(Source: Illumina Inc) Verinata Health Announces Agreement with Teva Pharmaceutical Industries in Collaboration with MOR Institute for Medical Data to Commercialize the verifi® Prenatal Test in Israel Agreement Establishes Patient Registry for Clinical Outcomes Data REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jul. 1, 2013-- Illumina, Inc. (NASDAQ: ILMN) today announced that Teva Pharmaceutical Industries Ltd. signed an exclusive agreement with Verinata Health, an Illumina company, for the commercialization of the verifi® non-invasive prenatal test1 in Israel. The MOR Institute for Medical Data Ltd., through its relationship with Teva, will provide the verifi® prenatal test to customers of Clalit...
↧